Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2016 19:03 ET | Source: Mesoblast Limited

Mesoblast Reports Financial Results for Period Ended 31 March 2016 and Provides Corporate Update

MELBOURNE, Australia and NEW YORK, May 09, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today reported its consolidated financial results and operational highlights for...
May 06, 2016 08:52 ET | Source: Mesoblast Limited

Mesoblast to Host Third Quarter and Nine Months Financial Results Conference Call and Webcast

NEW YORK and MELBOURNE, Australia, May 06, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the third quarter/nine months...
April 01, 2016 06:00 ET | Source: Mesoblast Limited

Mesoblast Cell Therapy Shows Disease Modifying Effects on Knee Osteoarthritis

NEW YORK and MELBOURNE, Australia, April 01, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that results from its Phase 2a trial in patients with...
March 24, 2016 08:15 ET | Source: Mesoblast Limited

Key United States Patent Granted for Cell-Based Treatment of Rheumatoid Arthritis and Other Rheumatic Conditions

NEW YORK and MELBOURNE, Australia, March 24, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the United States Patent and Trademark Office has granted a key...
March 17, 2016 06:00 ET | Source: Mesoblast Limited

New Mesoblast Cell Targeting Technology Shows Potential to Induce Durable Reversal of Type 1 Diabetes

NEW YORK and MELBOURNE, Australia, March 17, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Company has exclusively licensed patented technology...
February 24, 2016 06:00 ET | Source: Mesoblast Limited

First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee

NEW YORK and MELBOURNE, Australia, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., today launched...
February 22, 2016 05:00 ET | Source: Mesoblast Limited

Mesoblast’s Cell Therapy Increases Survival in Children With Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB;) today announced that results have been presented showing that use of its proprietary...
February 16, 2016 16:40 ET | Source: Mesoblast Limited

Mesoblast Reports on First Half and Second Quarter Financial Results

MELBOURNE, Australia and NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today reported financial results and operational highlights for the 1H/2Q ended 31...
February 16, 2016 06:00 ET | Source: Mesoblast Limited

Mesoblast Cell Therapy Shows Clinical Benefit in First Cohort of Patients With Biologic Refractory Rheumatoid Arthritis

NEW YORK and MELBOURNE, Australia, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced results from the first cohort of its ongoing Phase 2 trial in...
February 11, 2016 11:00 ET | Source: Mesoblast Limited

Mesoblast to Host Second Quarter and First Half Financial Results Conference Call and Webcast

MELBOURNE, Australia and NEW YORK, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year...